Send to

Choose Destination
Semin Immunol. 2010 Jun;22(3):113-24. doi: 10.1016/j.smim.2010.03.001. Epub 2010 Apr 18.

Chemotherapy and radiotherapy: cryptic anticancer vaccines.

Author information

INSERM, U805, F-94805 Villejuif, France; Institut Gustave Roussy, F-94805 Villejuif, France; Université Paris-Sud, F-94805 Villejuif, France.


An attractive, yet hitherto unproven concept predicts that the promotion of tumor regression should elicit the host's immune response against residual tumor cells to achieve an optimal therapeutic effect. In a way, chemo- or radiotherapy must trigger "danger signals" emitted from immunogenic cell death and hence elicit "danger associated molecular patterns" to stimulate powerful anticancer immune responses. Here, based on the recent experimental and clinical evidence, we will discuss the molecular identity of the multiple checkpoints that dictate the success of "immunogenic chemotherapy" at the levels of the drug, of the tumor cell and of the host immune system.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center